The tumor burden of CD19+ B-LCLs was measured by flow cytometry in liver, lung spleen, kidney, bone marrow tissues and blood from five groups (Gating strategy: Supplementary Fig. 11A). The gene discussed is CD19; the disease is neoplasm.